Results 231 to 240 of about 66,268 (303)

Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Aim Adverse events (AEs) detected in tweets and in the FDA Adverse Event Reporting System (FAERS) provide valuable insights into patient experiences with oral hypoglycemic agents including sodium‐glucose transporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP4) inhibitors. This study compared the side effects identified from tweets with those in
Se‐Hoon Oh, Dong‐Young Park, Yun‐Kyoung Song   +2 more
wiley   +1 more source

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source

Quality control of protein import into mammalian mitochondria

Protein Science, Volume 35, Issue 5, May 2026.
Abstract Mitochondrial function depends on the continuous import of hundreds of nuclear‐encoded proteins. Targeting and translocation of mitochondrial proteins is a multistep process that is inherently vulnerable to defects in cytosolic quality control systems as well as perturbations in mitochondrial protein import machinery and organelle function ...
Madeleine Goldstein, Laurie Lee‐Glover, Hilla Weidberg   +2 more
wiley   +1 more source

Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]

Diabetes Obes Metab
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB.   +5 more
europepmc   +1 more source

Correlation Analysis of 24‐h Minimum Heart Rate Levels and Deceleration Capacity of Heart Rate in Patients With Type 2 Diabetes Mellitus Complicated With Essential Hypertension

Annals of Noninvasive Electrocardiology, Volume 31, Issue 3, May 2026.
Sex‐specific 24‐hour minimum heart rate (MHR) stratification in patients with type 2 diabetes mellitus and essential hypertension (T2DM‐EH). Three key findings are shown from subgroup analysis: (1) In the normal MHR group (Group B), advancing age independently predicts reduced deceleration capacity (DC) in both sexes.
Pingping Wu, Zhengrong Xu, Xiuyu Zheng, Linying Gong, Hongkun Qiao, Guoyan Xu, Qunfang Xie   +6 more
wiley   +1 more source

Unique Role of Proximal Tubule Dipeptidyl Peptidase 4 on Blood Pressure, Renal Sodium Handling, and Na⁺/H⁺ Exchanger Isoform 3 Phosphorylation. [PDF]

Acta Physiol (Oxf)
Martins FL, Ribeiro-Silva JC, de Jesus EF, Nistala R, Girardi ACC.   +4 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer. [PDF]

Br J Cancer
Stange C, Dreyer TF, Riedel M, Elsen F, Seitz S, Hamann D, Kiechle M, Bronger H.   +7 more
europepmc   +1 more source

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. [PDF]

J Intern Med
Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY, Wang MT.   +6 more
europepmc   +1 more source